Final data from a landmark clinical trial of four Ebola therapies conducted in the current outbreak in the Democratic Republic of the Congo show two of the drugs dramatically reduced the risk of dying from the disease, especially in people who started treatment quickly after onset of their illness.
Findings of the PALM trial, published in the New England Journal of Medicine on [November 27], show that two treatments based on Ebola antibodies led to a survival rate of about 65% in treated patients, compared to 33% in the outbreak overall.
The trial tested the two treatments against a third antibody product, ZMapp, and the antiviral drug remdesivir, made by Gilead Sciences (GILD). They did not perform as well, saving only about half of the patients who were treated with one of those two therapies.
The trial began in November of last year, eventually enrolling 673 people who were randomized to get one of the four treatments. It ended early, in August of this year, because an interim analysis showed the two drugs were statistically better than ZMapp and remdesivir.
Read full, original post: Two Ebola treatments yield ‘substantial decrease’ in mortality, landmark trial shows